Insider Trading History of Mendelson Alan C

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) by Mendelson Alan C since 2005. The trader's CIK number is 1073381. At the time of the last reporting, Mendelson Alan C was the Director of Novelion Therapeutics Inc.. (stock ticker symbol NVLNF). Also see all insider trading activities at Novelion Therapeutics Inc..

Note that in the past MENDELSON ALAN C also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Novelion Therapeutics Inc. (QLTI) by Mendelson Alan C

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2007 QLTI 12,000 $60,930 0 $0 0 $0
2005 QLTI 2,000 $18,910 0 $0 0 $0

Yearly summary of insider trading at Valentis Inc (VLTS) by Mendelson Alan C

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2005 VLTS 6,000 $14,835 0 $0 0 $0


Insider trading activities at 2 companies by Mendelson Alan C:

1. Novelion Therapeutics Inc. (QLTI)

2. Valentis Inc (VLTS)

Table 1. Insider trading of Novelion Therapeutics Inc. (QLTI) by Mendelson Alan C

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2007-10-30 QLTI Buy 5,000 4.69 23,450
2007-10-26 QLTI Buy 5,000 4.59 22,950
2007-05-03 QLTI Buy 2,000 7.26 14,530
2005-08-01 QLTI Buy 1,000 8.53 8,530
2005-04-29 QLTI Buy 1,000 10.38 10,380

Table 2. Insider trading of Valentis Inc (VLTS) by Mendelson Alan C

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2005-12-21 VLTS Buy 1,000 1.64 1,641
2005-07-11 VLTS Buy 5,000 2.64 13,194

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Mendelson Alan C (Director of Novelion Therapeutics Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.